Alerid
Alfacip
Amlopres
Ampisyn
Beclate
Budecort
Carloc
Cefasyn
Cefoprox
Cephadex
Ciplactin
Citadep
Clopivas
Cobix
Cromal
Cytomid
Cytotam
Danogen
Diaglip
Dilvas
Doxacard
Duolin
Duovir
Emeset
Etosid
Famtrex
Fertomid
Fincar
Flohale
Flomist
Forcan
Ginette
Glumet
Hipres
Ibugesic
Ipravent
Lomac
Mebex
Metolar
Misoprost
Modafinil
Montair
Norflox
Novamox
Osteofos
Oxyspas
Pantosec
Paracip
Pirox
Pletoz
Ralista
Ramipres
Serobid
Seroflo
Stavir
Terol
Tibofem
Tiova
Tramacip
Ulcimax
Venlor
Warf
Zidovir
Zoflut
|
Buy Warf now!
Warf.
Warf-1 = Warfarin Sodium (crystalline) USP equivalent to Warfarin Sodium (anhydrous) 1mg
Warf-2 = Warfarin Sodium (crystalline) USP equivalent to Warfarin Sodium (anhydrous) 2mg
Warf-5 = Warfarin Sodium (crystalline) USP equivalent to Warfarin Sodium (anhydrous) 5mg
Preventive maintenance and-or treatment venous thrombosis and its expansions,
pulmonary embolism, preventive maintenance and-or treatment thromboembolic
complications have contacted purchase of fibrous structure concerning to an auricle and-or a mitral valve
replacement and post heart attack of a myocardium.
The dosage and administration Warf should be individualized for everyone
the patient it agrees PT/INR to the answer of the specific patient to a drug.
Venous thrombo-embolism (including pulmonary embolism): INR 2.0-
3.0 Is sufficient for preventive maintenance and treatment venous thrombo-embolism
also minimizes risk of the haemorrhage connected with higher INRs.
Purchase of fibrous structure concerning to an auricle: INR 2.0-3.0 it should be used for long Warf term
therapy in corresponding patients.
Post heart attack of a myocardium: In post patients of a heart attack of a myocardium, Warf
therapy should be started early (a postheart attack of 2-4 weeks) and a dosage
should be adjusted to support INR 2.5-3.5 long terms. In patients
the idea to be at the increased risk of bleeding complications or on aspirin
therapy, service of therapy Warf in lower end of this range INR
it is recommended.
Mechanical and Bioprosthetic mitral valves: In patients with mechanical
mitral valve, for a long time name preventive maintenance with Warf to INR 2.5-3.5
recommended. In patients with bioprosthetic mitral valves, therapy Warf
to INR 2.0-3.0 within 12 weeks after the insert is recommended. In patients
with additional risk factors such as purchase of fibrous structure concerning to an auricle or previous thrombo-embolism, consideration needs to be given for long therapy of term.
Current system embolism: In cases, where risk thrombo-embolism
Is big, type in patients with current system of embolism, higher INR
it can be required.
INR is more than 4.0, apparently, does not provide any additional therapeutic
benefit in the majority of patients also is connected to higher risk of a bleeding
initial dose: it is recommended, that therapy Warf has been started with a
the dose 2 - 5 mg day with regulators of a dosage was based on results
PT/INR Definitions. Low doses of initiation are recommended for elderly
and-or the exhausted patients and patients with potential to show it is more
than expected PT/INR the answer on Warf.
Service: the Majority of patients is well served in a dose 2 to
10 mg daily.
Duration of therapy: duration of therapy in each patient should be
individualized. In general, therapy of anticoagulant should not be continued up to
danger thrombosis and embolism has passed.
Transformation from heparin therapies: Since effect of anticoagulant Warf
it is deferred, heparin is preferred originally for fast anticoagulation.
Transformation to Warf can begin concomitantly with heparin therapies or
can be deferred on 3 - 6 days. To guarantee continuous anticoagulation, it
desirable to continue a full dose heparin therapy and that therapy Warf
be crossed with heparin during 4 - 5 days while Warf has not made
the desirable therapeutic answer as it is determined PT/INR. As soon as it has
achieved, heparin can be stopped.
| Warnings and Precautions. |
For anticoagulation serve as contra-indication in anyone limited or the general physical
condition or personal circumstance, in which danger haemorrhage
could be more than potential clinical benefits from anticoagulation such
as: pregnancy, hemorrhagic tendencies or blood dyscrasias; recent or
considered surgery: (1) central nervous system, (2) eyes, (3) injuring
surgery, coming to an end the big open surfaces; bleeding tendencies have communicated
with active ulceration or a frank bleeding: (1) gastrointestinal, urinogenital
or respiratory treatises, (2) a cerebrovascular haemorrhage, (3) aneurysms
brain, dissecting an aorta, (4) pericarditis and pericardial outpourings, (5)
bacterial endocarditis, threatened abortion, eclampsia and pre-eclampsia;
inadequate laboratory means of service; uncontrollable patients with an old age,
alcoholism, either psychosis or other lack of patient cooperation; back
pierce also other diagnostic or therapeutic procedures with potential for
bleeding not giving in to the control; the main regional, lumbar anesthesia of the block and
malicious hypertension.
|
|